Attached files
file | filename |
---|---|
8-K - 8-K - AEOLUS PHARMACEUTICALS, INC. | v211758_8k.htm |
EX-10.1 - EX-10.1 - AEOLUS PHARMACEUTICALS, INC. | v211758_ex10-1.htm |
Exhibit
99.1
Contact:
Russell
Skibsted
Sr. Vice
President and Chief Financial Officer
Aeolus
Pharmaceuticals, Inc.
(949)
481-9825
AEOLUS
PHARMACEUTICALS ANNOUNCES APPOINTMENT OF RUSSELL L. SKIBSTED AS SENIOR VICE
PRESIDENT AND CHIEF FINANCIAL OFFICER
MISSION VIEJO, California –
February 15, 2011— Aeolus Pharmaceuticals, Inc. (OTC: AOLS), a biopharmaceutical
company developing a new class of broad spectrum catalytic antioxidant compounds
that reduce oxidative stress, inflammation, and subsequent tissue
damage-signaling cascades resulting from radiation exposure, today announced the
appointment of Russell L. Skibsted as Senior Vice President and Chief Financial
Officer.
“We
welcome Russell to the Aeolus team and are pleased to have an accomplished
professional of his caliber leading our financial operations,” said John L.
McManus, President and Chief Executive Officer of Aeolus Pharmaceuticals, Inc.
“His extensive financial management experience, strategic planning skills, and
leadership will be outstanding assets to Aeolus as we enter the next phase of
our company’s development and transition to a period of rapid
growth”
Mr.
Skibsted is a seasoned executive with over 25 years of experience in finance,
acquisitions, partnering, marketing and operations, with companies ranging from
start-ups to a Fortune 5. He has significant private equity, public market,
operations and transaction experience with both public and private
companies. Prior to joining Aeolus, he was Senior Vice President and
Chief Business Officer of Spectrum Pharmaceuticals (NASDAQ: SPPI) where he led
global strategy, M&A, licensing, fund-raising, & IR/PR. At Spectrum he
completed a significant partnership and an asset sale that generated over $62
million in non-dilutive funding to the company in 2008. Previously,
he was CFO at Hana Biosciences (NASDAQ: HNAB)[now Talon Therapeutics (OTC:
TLON.OB)], where he led the process of bringing the company public &
completed two financings. Before joining Hana, Mr. Skibsted was Partner and CFO
at Asset Management Company, one of the oldest and most respected venture
capital firms in the Silicon Valley, where he oversaw the financial &
administrative functions, public & private portfolios, & aviation
operations. Russell Skibsted earned an MBA from the Stanford Graduate
School of Business and a BA in economics from Claremont McKenna
College.
About
AEOL 10150
AEOL
10150 is a broad-spectrum catalytic antioxidant specifically designed to
neutralize reactive oxygen and nitrogen species. The neutralization of these
species reduces oxidative stress, inflammation, and subsequent tissue
damage-signaling cascades resulting from radiation exposure. AEOL
10150 could have a profound beneficial impact on people who have been exposed,
or are about to be exposed, to high-doses of radiation in the treatment of
oncology.
AEOL
10150 has already performed well in animal safety studies, was well-tolerated in
two human clinical trials, and has demonstrated statistically significant
survival efficacy in an acute radiation-induced lung injury model. AEOL 10150 is
also currently in development for use as both a therapeutic and prophylactic
drug in cancer patients.
About
Aeolus Pharmaceuticals
Aeolus
Pharmaceuticals is developing a new class of catalytic antioxidant compounds
that protects healthy tissue from the damaging effects of
radiation. Its first compound, AEOL 10150, is being developed for
oncology indications, where it is used in combination with radiation
therapy. It is also being developed, with funding by the US
Government, as a medical countermeasure against chemical and radiological
weapons, where its initial target indications are as a protective agent against
the effects of acute radiation syndrome and delayed effects of acute radiation
exposure. Aeolus’ strategy is to leverage the substantial
investment in toxicology, manufacturing, and preclinical and clinical studies
made by US Government agencies in AEOL 10150 to efficiently develop the compound
for use in oncology. For more information, please visit Aeolus’s
corporate website at www.aeoluspharma.com.
The
statements in this press release that are not purely statements of historical
fact are forward-looking statements. Such statements include, but are not
limited to, those relating to Aeolus’ product candidates, as well as its
proprietary technologies and research programs. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may cause
Aeolus’ actual results to be materially different from historical results or
from any results expressed or implied by such forward-looking statements.
Important factors that could cause results to differ include risks associated
with uncertainties of progress and timing of clinical trials, scientific
research and product development activities, difficulties or delays in
development, testing, obtaining regulatory approval, the need to obtain funding
for pre-clinical and clinical trials and operations, the scope and validity of
intellectual property protection for Aeolus’ product candidates, proprietary
technologies and their uses, and competition from other biopharmaceutical
companies. Certain of these factors and others are more fully described in
Aeolus’ filings with the Securities and Exchange Commission, including, but not
limited to, Aeolus’ Annual Report on Form 10-K for the year ended September 30,
2009. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof.
*****
2